{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:44:07Z","timestamp":1764791047923,"version":"3.46.0"},"reference-count":25,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Kirsten-RAS (KRAS) mutations play an important role in the carcinogenesis of a subset of lung adenocarcinomas and are associated with poorer prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the relationship of KRAS mutation status to the histologic subtype of adenocarcinoma according to the recent classification, patient demographics, tumor size, predominant histologic subtype, nodal status, and visceral pleural invasion, in an attempt to uncover the reason for the worse prognosis associated with KRAS mutation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A total of 187 consecutive resected lung adenocarcinomas from our institution from 2008 to 2011 that were diagnosed according to the new International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society classification and screened for KRAS mutations were included in the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 32% of the adenocarcinomas harbored the KRAS mutation. The median age in the KRAS mutation group was 69 years (range, 43\u201386 years), and male to female ratio was 1:2.3. The proportion of heavy smokers was significantly higher in tumors with KRAS mutation compared with wild type (83% versus 62%; P = .01). A total of 27% of tumors with KRAS mutation had pleural invasion versus 11% of tumors without KRAS mutation (P = .009). A total of 59 tumor samples were positive for KRAS mutation (25 for G12C, 14 for G12A, 8 for G12V, 7 for G12D, 3 for G12S, and 1 for G12T), and only 3 tumors harbored codon 13 mutations (G13C). Two tumors had double mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>KRAS mutations are more common in heavy smokers, and lung adenocarcinomas with KRAS mutation are more likely to invade the visceral pleura. Increased frequency of visceral pleural invasion may explain in part the worse prognosis associated with KRAS mutations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2013-0759-oa","type":"journal-article","created":{"date-parts":[[2014,4,2]],"date-time":"2014-04-02T09:54:15Z","timestamp":1396432455000},"page":"189-193","source":"Crossref","is-referenced-by-count":7,"title":["Peripheral Lung Adenocarcinomas With KRAS Mutations Are More Likely to Invade Visceral Pleura"],"prefix":"10.5858","volume":"139","author":[{"given":"Kirtee","family":"Raparia","sequence":"first","affiliation":[{"name":"From the Departments of Pathology (Drs Raparia and Villa), and Pulmonary and Critical Care (Dr Raj), Northwestern University, Chicago, Illinois; and the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (Dr Cagle)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celina","family":"Villa","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology (Drs Raparia and Villa), and Pulmonary and Critical Care (Dr Raj), Northwestern University, Chicago, Illinois; and the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (Dr Cagle)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishi","family":"Raj","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology (Drs Raparia and Villa), and Pulmonary and Critical Care (Dr Raj), Northwestern University, Chicago, Illinois; and the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (Dr Cagle)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip T.","family":"Cagle","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology (Drs Raparia and Villa), and Pulmonary and Critical Care (Dr Raj), Northwestern University, Chicago, Illinois; and the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (Dr Cagle)."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","published-online":{"date-parts":[[2014,4,2]]},"reference":[{"issue":"1","key":"2020081222214541300_i1543-2165-139-2-189-b01","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"2020081222214541300_i1543-2165-139-2-189-b02","unstructured":"William D. Travis EB, M\u00fcller-Hermelink HK, Harris CC. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press;2004."},{"issue":"2","key":"2020081222214541300_i1543-2165-139-2-189-b03","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","article-title":"International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma","volume":"6","author":"Travis","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"4","key":"2020081222214541300_i1543-2165-139-2-189-b04","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/JTO.0b013e31820a3a6b","article-title":"Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer","volume":"6","author":"Ludovini","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2020081222214541300_i1543-2165-139-2-189-b05","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0020017","article-title":"KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"issue":"8","key":"2020081222214541300_i1543-2165-139-2-189-b06","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.2012.46.9270","article-title":"New pathologic classification of lung cancer: relevance for clinical practice and clinical trials","volume":"31","author":"Travis","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020081222214541300_i1543-2165-139-2-189-b07","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1200\/JCO.2005.04.3224","article-title":"Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas","volume":"24","author":"Pham","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020081222214541300_i1543-2165-139-2-189-b08","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.5858\/133.10.1552","article-title":"Protocol for the examination of specimens from patients with primary non-small cell carcinoma, small cell carcinoma, or carcinoid tumor of the lung","volume":"133","author":"Butnor","year":"2009","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"2020081222214541300_i1543-2165-139-2-189-b09","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ab.2009.05.027","article-title":"Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues","volume":"391","author":"Dufort","year":"2009","journal-title":"Anal Biochem"},{"key":"2020081222214541300_i1543-2165-139-2-189-b10","unstructured":"American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. Chicago, IL: Springer;2009."},{"issue":"2","key":"2020081222214541300_i1543-2165-139-2-189-b11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/JTO.0b013e318160c607","article-title":"Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma","volume":"3","author":"Marks","year":"2008","journal-title":"J Thorac Oncol"},{"issue":"2","key":"2020081222214541300_i1543-2165-139-2-189-b12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/cncr.27730","article-title":"Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas","volume":"119","author":"Johnson","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"2020081222214541300_i1543-2165-139-2-189-b13","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1245\/s10434-012-2754-z","article-title":"KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy","volume":"20","author":"Guan","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2020081222214541300_i1543-2165-139-2-189-b14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1513\/pats.200809-107LC","article-title":"KRAS mutations in non-small cell lung cancer","volume":"6","author":"Riely","year":"2009","journal-title":"Proc Am Thorac Soc"},{"issue":"4637","key":"2020081222214541300_i1543-2165-139-2-189-b15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1126\/science.6695174","article-title":"Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient","volume":"223","author":"Santos","year":"1984","journal-title":"Science"},{"issue":"1","key":"2020081222214541300_i1543-2165-139-2-189-b16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JTO.0b013e3182769aa8","article-title":"Validation of the IASLC\/ATS\/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients","volume":"8","author":"Yoshizawa","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2020081222214541300_i1543-2165-139-2-189-b17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.lungcan.2012.09.018","article-title":"Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose","volume":"79","author":"Li","year":"2013","journal-title":"Lung Cancer"},{"issue":"3","key":"2020081222214541300_i1543-2165-139-2-189-b18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s13402-012-0078-4","article-title":"EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma","volume":"35","author":"Smits","year":"2012","journal-title":"Cell Oncol (Dordr)"},{"issue":"10","key":"2020081222214541300_i1543-2165-139-2-189-b19","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/modpathol.2013.74","article-title":"KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma","volume":"26","author":"Rekhtman","year":"2013","journal-title":"Mod Pathol"},{"issue":"18","key":"2020081222214541300_i1543-2165-139-2-189-b20","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1158\/1078-0432.CCR-08-0646","article-title":"Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma","volume":"14","author":"Riely","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2020081222214541300_i1543-2165-139-2-189-b21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/JTO.0b013e3182828fb8","article-title":"Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC\/ATS\/ERS lung adenocarcinoma classification in stage III (N2) patients","volume":"8","author":"Russell","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"18","key":"2020081222214541300_i1543-2165-139-2-189-b22","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1002\/cncr.26010","article-title":"Clinicopathological features of lung adenocarcinoma with KRAS mutations","volume":"117","author":"Kakegawa","year":"2011","journal-title":"Cancer"},{"issue":"8","key":"2020081222214541300_i1543-2165-139-2-189-b23","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/JTO.0b013e3181e2a2bc","article-title":"Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma","volume":"5","author":"Hata","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"22","key":"2020081222214541300_i1543-2165-139-2-189-b24","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1158\/1078-0432.CCR-11-3265","article-title":"Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers","volume":"18","author":"Dogan","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2020081222214541300_i1543-2165-139-2-189-b25","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/JTO.0b013e3181a85d5e","article-title":"Visceral pleura invasion impact on non-small cell lung cancer patient survival: its implications for the forthcoming TNM staging based on a large-scale nation-wide database","volume":"4","author":"Yoshida","year":"2009","journal-title":"J Thorac Oncol"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/139\/2\/189\/1613539\/arpa_2013-0759-oa.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/139\/2\/189\/1613539\/arpa_2013-0759-oa.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:35:47Z","timestamp":1764790547000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/139\/2\/article-p189.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,2]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,4,2]]},"published-print":{"date-parts":[[2015,2,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2013-0759-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"type":"electronic","value":"1543-2165"},{"type":"print","value":"0003-9985"}],"subject":[],"published":{"date-parts":[[2014,4,2]]}}}